2012 Scrip 100: Taking a biological approach to generic evolution - an interview with Actavis' Claudio Albrecht
09 December 2011
Mike Ward
Please Login to read the full article.
09 December 2011
Mike Ward
Please Login to read the full article.
RELATED CONTENT
NEWS
- 2012 Scrip 100 Preview: Base jumping for pharma – a slower descent from the patent cliff?
- Hikma rolls into Morocco with $158 million Promopharm buy
- European generics firms, squeezed between innovators and payers, seek diversity
- Brand vs generic: the battle rages over EU counterfeit 'safety features'
COMMENT
Other Informa Comment
FEATURES
- Chinese producers may be losing price edge to India, says Granules MD
- Merck BioVentures: where biosimilars make a difference
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
